Sign In
Buy DGX
$193.67
+0.510 (+0.264%)
At Close: Jun 03, 2026
Head to Head Review: Super Nova Resources (OTCMKTS:SNRR) vs. Quest Diagnostics (NYSE:DGX)
01:32am, Sunday, 02'nd Nov 2025
Super Nova Resources (OTCMKTS:SNRR - Get Free Report) and Quest Diagnostics (NYSE: DGX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
10:41am, Monday, 27'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
07:45am, Monday, 27'th Oct 2025
The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation SECAUCUS, N.J. , Oct. 27, 2025 /PRNewswire/ -- Two bloo
Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead
03:10pm, Wednesday, 22'nd Oct 2025
Quest Diagnostics Incorporated announced its Q3 earnings yesterday - revenues year-to-date are $8.23bn, and net income $845m. DGX is finally demonstrating a strong post-pandemic recovery, with Q3 reve
Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings
01:19pm, Wednesday, 22'nd Oct 2025
Quest Diagnostics (NASDAQ:DGX) posted better-than-expected earnings for the third quarter on Tuesday.
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
10:46am, Wednesday, 22'nd Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Incorporated (DGX) Q3 2025 Earnings Call Transcript
11:54am, Tuesday, 21'st Oct 2025
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Shawn Bevec - Vice President of Investor Relations James Davis - Chairman, CEO & Pres
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
10:31am, Tuesday, 21'st Oct 2025
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates
08:55am, Tuesday, 21'st Oct 2025
Quest Diagnostics (DGX) came out with quarterly earnings of $2.6 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.3 per share a year ago.
Quest Diagnostics raises annual profit and revenue forecasts on lab test demand
07:16am, Tuesday, 21'st Oct 2025
Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests.
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
06:45am, Tuesday, 21'st Oct 2025
Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Tuesday, 14'th Oct 2025
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Tuesday, 14'th Oct 2025
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
09:40am, Tuesday, 14'th Oct 2025
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
Quest Diagnostics: Investing In Healthcare's Future Today
12:49am, Monday, 06'th Oct 2025
Quest Diagnostics (DGX) remains a buy, which is also what the consensus today said too. Quest can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas.
